TrialPloS one2015

A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.

Richard N Greenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.